Episode 482: Why the Framingham Heart Study Still Matters episode artwork

EPISODE · Feb 17, 2026 · 24 MIN

Episode 482: Why the Framingham Heart Study Still Matters

from Heart Doc VIP with Dr. Joel Kahn

This week on Heart Doc VIP, Dr. Joel Kahn takes a deep dive into one of the most influential research projects in cardiovascular history: the Framingham Heart Study. Launched in 1948 and still going strong, this landmark study helped identify many of the risk factors we now take for granted, including smoking, diabetes, high cholesterol, high blood pressure, obesity, and physical inactivity. Much of what modern cardiology considers "common knowledge" about prevention started in Framingham. Dr. Kahn also explores practical and emerging topics in heart health, including the role of magnesium and berberine supplementation, how to approach both low-carb and low-fat diets in a healthy way, and concerns about long-term proton pump inhibitor use. Additional discussion covers EECP therapy and strategies to improve coronary blood flow, along with the potential benefits of ezetimibe for cholesterol reduction and brain health. Thank you to this week's sponsor, Igennus. Visit igennus.com and use code DRKAHN for a special discount.

Episode metadata supplied by the publisher feed · Published Feb 17, 2026

Embed this episode

NOW PLAYING

Episode 482: Why the Framingham Heart Study Still Matters

0:00 24:22

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Heart Doc VIP with Dr. Joel Kahn?

This episode is 24 minutes long.

When was this Heart Doc VIP with Dr. Joel Kahn episode published?

This episode was published on February 17, 2026.

Can I download this Heart Doc VIP with Dr. Joel Kahn episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!